Cargando…

What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?

Detalles Bibliográficos
Autor principal:	Kim, Jin-Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813421/ https://www.ncbi.nlm.nih.gov/pubmed/31650721 http://dx.doi.org/10.3346/jkms.2019.34.e277

Ejemplares similares

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Direct-acting antiviral agents against hepatitis C virus and lipid metabolism
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
por: Sato, Ken, et al.
Publicado: (2022)

Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinoma
por: Sohn, Won
Publicado: (2021)

Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection
por: Matsumoto, Kotaro, et al.
Publicado: (2018)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease
por: Ryu, Ji Eun, et al.
Publicado: (2022)

Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C
por: Parums, Dinah V.
Publicado: (2023)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
por: Lee, Hye Won
Publicado: (2022)

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021)

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C
por: Yamazaki, Tomoo, et al.
Publicado: (2018)

Safety and efficacy of directly‐acting antiviral therapy for chronic hepatitis C virus in elderly people
por: De Santis, Adriano, et al.
Publicado: (2021)

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
por: Arruda, Raissa M, et al.
Publicado: (2020)

Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Estimation of Direct Medical Costs Related to Chronic Hepatitis C: A Rationale for Early Antiviral Therapy
por: Kim, Do Young
Publicado: (2017)

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
por: Chae, Hee Bok, et al.
Publicado: (2013)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus
por: Sato, Ken, et al.
Publicado: (2018)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
por: Gallach, Marta, et al.
Publicado: (2018)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Hepatitis C infected patients need vitamin D3 supplementation in the era of direct acting antivirals treatment
por: Kondo, Yasuteru
Publicado: (2017)

Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Liver cT(1) decreases following direct-acting antiviral therapy in patients with chronic hepatitis C virus
por: Jayaswal, Arjun N. A., et al.
Publicado: (2020)

Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
por: Childs, Kate, et al.
Publicado: (2017)

Patients’ preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection
por: Simón, MA, et al.
Publicado: (2021)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
por: Gaglio, Paul J., et al.
Publicado: (2011)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
por: Toshikuni, Nobuyuki
Publicado: (2017)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
por: Scott, Nick, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_183dk4n5ohlol0tk1oqdvguabq